Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agree… Read more
Intellia Therapeutics Inc (NTLA) - Net Assets
Latest net assets as of December 2025: $671.39 Million USD
Based on the latest financial reports, Intellia Therapeutics Inc (NTLA) has net assets worth $671.39 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($842.13 Million) and total liabilities ($170.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $671.39 Million |
| % of Total Assets | 79.73% |
| Annual Growth Rate | 50.35% |
| 5-Year Change | -35.46% |
| 10-Year Change | 219.96% |
| Growth Volatility | 226.07 |
Intellia Therapeutics Inc - Net Assets Trend (2014–2025)
This chart illustrates how Intellia Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intellia Therapeutics Inc (2014–2025)
The table below shows the annual net assets of Intellia Therapeutics Inc from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $671.39 Million | -23.00% |
| 2024-12-31 | $871.96 Million | -16.97% |
| 2023-12-31 | $1.05 Billion | -15.01% |
| 2022-12-31 | $1.24 Billion | +18.78% |
| 2021-12-31 | $1.04 Billion | +97.36% |
| 2020-12-31 | $527.07 Million | +95.30% |
| 2019-12-31 | $269.88 Million | -2.89% |
| 2018-12-31 | $277.92 Million | -7.54% |
| 2017-12-31 | $300.60 Million | +43.25% |
| 2016-12-31 | $209.84 Million | +211.53% |
| 2015-12-31 | $67.36 Million | +790.25% |
| 2014-12-31 | $7.57 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intellia Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 258055500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $12.00K | 0.00% |
| Other Comprehensive Income | $1.03 Million | 0.15% |
| Other Components | $3.26 Billion | 485.62% |
| Total Equity | $671.39 Million | 100.00% |
Intellia Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Intellia Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TODCF
OTCGREY:TODCF
|
$1.51 Billion |
|
Ecovacs Robotics Co Ltd
SHG:603486
|
$1.52 Billion |
|
China Power International Development Limited
F:HPD
|
$1.52 Billion |
|
FOCI Fiber Optic Communications
TWO:3363
|
$1.52 Billion |
|
ASGN Inc
NYSE:ASGN
|
$1.51 Billion |
|
Far Eastern International Bank
TW:2845
|
$1.51 Billion |
|
Harvey Norman Holdings Ltd
PINK:HNORF
|
$1.51 Billion |
|
Blackbaud Inc
NASDAQ:BLKB
|
$1.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intellia Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 871,956,000 to 671,394,000, a change of -200,562,000 (-23.0%).
- Net loss of 412,694,000 reduced equity.
- New share issuances of 128,175,000 increased equity.
- Other comprehensive income increased equity by 427,000.
- Other factors increased equity by 83,530,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-412.69 Million | -61.47% |
| Share Issuances | $128.18 Million | +19.09% |
| Other Comprehensive Income | $427.00K | +0.06% |
| Other Changes | $83.53 Million | +12.44% |
| Total Change | $- | -23.00% |
Book Value vs Market Value Analysis
This analysis compares Intellia Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.33x to 2.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.74 | $13.48 | x |
| 2015-12-31 | $3.81 | $13.48 | x |
| 2016-12-31 | $6.06 | $13.48 | x |
| 2017-12-31 | $8.35 | $13.48 | x |
| 2018-12-31 | $6.45 | $13.48 | x |
| 2019-12-31 | $5.71 | $13.48 | x |
| 2020-12-31 | $9.41 | $13.48 | x |
| 2021-12-31 | $14.67 | $13.48 | x |
| 2022-12-31 | $16.05 | $13.48 | x |
| 2023-12-31 | $11.83 | $13.48 | x |
| 2024-12-31 | $8.82 | $13.48 | x |
| 2025-12-31 | $6.20 | $13.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intellia Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -609.85%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.25x
- Recent ROE (-61.47%) is below the historical average (-47.22%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -189.12% | 0.00% | 0.00x | 1.41x | $-15.07 Million |
| 2015 | -18.41% | -205.11% | 0.07x | 1.22x | $-19.13 Million |
| 2016 | -15.08% | -191.97% | 0.06x | 1.42x | $-52.62 Million |
| 2017 | -22.47% | -258.62% | 0.07x | 1.25x | $-97.60 Million |
| 2018 | -30.71% | -280.42% | 0.09x | 1.25x | $-113.14 Million |
| 2019 | -36.88% | -230.92% | 0.13x | 1.24x | $-126.52 Million |
| 2020 | -23.82% | -216.52% | 0.09x | 1.28x | $-178.28 Million |
| 2021 | -24.97% | -785.76% | 0.03x | 1.24x | $-363.74 Million |
| 2022 | -38.38% | -909.78% | 0.03x | 1.23x | $-597.74 Million |
| 2023 | -45.82% | -1326.51% | 0.03x | 1.24x | $-586.21 Million |
| 2024 | -59.52% | -896.77% | 0.05x | 1.37x | $-606.22 Million |
| 2025 | -61.47% | -609.85% | 0.08x | 1.25x | $-479.83 Million |
Industry Comparison
This section compares Intellia Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intellia Therapeutics Inc (NTLA) | $671.39 Million | -189.12% | 0.25x | $1.51 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |